Join to View Full Profile
12697 E 51st StTulsa, OK 74146
Phone+1 918-505-3200
Fax+1 918-505-3253
Dr. Keller is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
National Institutes of Health Clinical CenterFellowship, Medical Oncology, 1977
Boston University Medical CenterResidency, Internal Medicine, 1973 - 1975
University of Oklahoma College of MedicineClass of 1973
Certifications & Licensure
OK State Medical License 1978 - 2025
CO State Medical License 2004 - 2005
MD State Medical License 1975 - 1980
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012-2013
Clinical Trials
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2009 Apr 01
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary Start of enrollment: 2009 Sep 01
- Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma Start of enrollment: 2010 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 363 citationsPhase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung CancerGiorgio V. Scagliotti, Silvia Novello, Joachim von Pawel, Martin Reck, José Rodrigues Pereira
Journal of Clinical Oncology. 2010-04-10 - 61 citationsAdjuvant Therapy With the Monoclonal Antibody Edrecolomab Plus Fluorouracil-Based Therapy Does Not Improve Overall Survival of Patients With Stage III Colon CancerAnthony L.A. Fields, Alan Keller, Lee S. Schwartzberg, Stephen A. Bernard, Carl Kardinal
Journal of Clinical Oncology. 2009-04-20 - 158 citationsRandomized Phase III Trial of Pegylated Liposomal Doxorubicin Versus Vinorelbine or Mitomycin C Plus Vinblastine in Women With Taxane-Refractory Advanced Breast CancerAlan M. Keller, Robert G. Mennel, Vassilis A. Georgoulias, Jean Marc Nabholtz, Aura Erazo
Journal of Clinical Oncology. 2004-10-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
